Business Wire

Berkshire Hathaway Specialty Insurance Names Regional Leaders for Europe and the Middle East

Share

Berkshire Hathaway Specialty Insurance (BHSI) today announced that it has appointed two BHSI leaders to regional leadership positions. Alessandro Cerase has been appointed President & Head of Europe Region, and Neeraj Yadvendu is now Head of Middle East and subject to regulatory approval, will concurrently take on the role of Senior Executive Officer of the Dubai International Financial Centre Branch.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230502005175/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Alessandro Cerase, Head of Europe Region (Photo: Business Wire)

Alessandro joined BHSI in 2018 as Senior Executive Officer (SEO) for BHSI Middle East and led the launch of BHSI’s business in the region. In 2020 he was named to the additional position of Global Property Underwriter Officer for Construction & Energy. He has more than 25 years of global insurance industry experience and has lived and worked in the UK, the U.S, and the Middle East. He will continue to be based in Dubai and report to Peter Eastwood, President and Chief Executive Officer, BHSI.

Neeraj joined BHSI in 2018 as Deputy Senior Executive Officer and Head of Third Party Lines in the Middle East and has played a pivotal role in BHSI’s growth in the region. He has more than 26 years of global insurance industry experience and has lived and worked in the UK, Asia, and the Middle East. Neeraj will continue to be based in Dubai and will report to Marc Breuil, Head of Asia Middle East, BHSI.

“BHSI has been growing steadily and strategically around the globe and at an accelerated pace in our Europe, and Middle East regions,” said Peter Eastwood. “Alessandro and Neeraj, and the stellar teams they have built, have been pivotal to this expansion. In their new roles, these two strong leaders will have an even greater impact as they continue to bring our underwriting flexibility and acumen, our CLAIMS IS OUR PRODUCT® commitment, and the certainty of our financial strength to customers and brokers throughout Europe and the Middle East.”

Berkshire Hathaway Specialty Insurance Company (incorporated in Nebraska, USA) provides commercial property, casualty, healthcare professional liability, executive and professional lines, transactional liability, surety, marine, travel, programs, accident and health, medical stop loss, homeowners, and multinational insurance. The actual and final terms of coverage for all product lines may vary. In the Asia Middle East region, it underwrites on the paper of Berkshire Hathaway Specialty Insurance Company (BHSIC). The Dubai International Financial Centre Branch of BHSI is regulated by the Dubai Financial Services Authority. In Europe, Berkshire Hathaway Specialty Insurance (BHSI) trades under Berkshire Hathaway European Insurance DAC (BHEI) and Berkshire Hathaway International Insurance Limited (BHIIL). BHEI is an Irish domiciled Designated Activity Company, Registration Number 636883 and Registered Office at 2nd Floor, 7 Grand Canal Street Lower, Dublin D02 KW81. Berkshire Hathaway International Insurance Limited (BHIIL), is an incorporated England and Wales limited liability company, Registration Number 3230337 and Registered Office at 8 Fenchurch Place, 4th Floor, London EC3M 4AJ, United Kingdom. BHSIC, BHIIL and BHEI are subsidiaries of Berkshire Hathaway's National Indemnity group of insurance companies, which hold financial strength ratings of A++ from AM Best and AA+ from Standard & Poor's. Based in Boston, Berkshire Hathaway Specialty Insurance has offices in Atlanta, Boston, Chicago, Columbia, Dallas, Houston, Indianapolis, Irvine, Los Angeles, New York, Plymouth Meeting, San Francisco, San Ramon, Seattle, Stevens Point, Adelaide, Auckland, Barcelona, Brisbane, Brussels, Cologne, Dubai, Dublin, Frankfurt, Hong Kong, Kuala Lumpur, London, Lyon, Macau, Madrid, Manchester, Melbourne, Munich, Paris, Perth, Singapore, Sydney, Toronto, and Zurich.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

JoAnn Lee / +1 617.936.2937

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rimini Street Announces Fiscal First Quarter 2024 Financial and Operating Results2.5.2024 14:05:00 EEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, products and services, the leading third-party support provider for Oracle and SAP software, and a Salesforce and AWS partner, today announced results for the fiscal first quarter ended March 31, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502994935/en/ Rimini Street Announces Fiscal First Quarter 2024 Financial and Operating Results (Graphic: Business Wire) Select First Quarter 2024 Financial Highlights Revenue was $106.7 million for the 2024 first quarter, an increase of 1.2% compared to $105.5 million for the same period last year. U.S. revenue was $53.8 million for the 2024 first quarter, an increase of 0.7% compared to $53.4 million for the same period last year. International revenue was $52.9 million for the 2024 first quarter, an increase of 1.6% compared to $52.1 million for the same period last year. Annuali

Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer2.5.2024 14:00:00 EEST | Press release

Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical innovation to treat people with cancer, today announced it will be acquired by Novartis for $1 billion upfront and up to $750 million in potential milestone payments. The acquisition brings together Mariana Oncology’s innovative radiopharmaceutical pipeline and platform with the proven clinical development and commercialization expertise of Novartis. Mariana Oncology has developed a robust portfolio of novel peptide based-radiopharmaceuticals targeting a broad spectrum of solid tumor cancers, and has invested in manufacturing capabilities, an extensive isotope supply chain and novel formulations to enhance final product shelf-life. The company’s lead program, MC-339, is a novel radioligand therapy (RLT) designed to target small cell lung cancer. “Novartis is an established leader in the commercialization of radiopharmaceuticals with a world-class team and global reach. Together, we of

Lifezone Metals to Provide its Q1 2024 Operational Update and Financial Summary on Monday, May 13, 20242.5.2024 13:30:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) will release its operational update and unaudited financial summary for the first quarter of 2024 before market open on Monday, May 13, 2024. The company invites shareholders, investors, and members of the media to join the executive team for a virtual presentation and discussion of the Q1 summary and outlook. The presentation will be followed by a Q&A session where participants can engage directly with Lifezone’s senior management. Event details: Date: Monday, May 13, 2024. Time: 10:00 AM Eastern Time. Location: Virtual (please click the webcast registration link). The presentation slides will be available on Lifezone’s website on the day of the release. The webcast will be archived and accessible for replay for a limited time after the event. If you would like to sign up for Lifezone Metals news alerts, please register here. About Lifezone Metals At Lifezone Metals (NYSE: LZM), our mission is to provide cleaner and more responsible metals productio

Florin Filote joins ThredUp as General Manager of Europe2.5.2024 13:00:00 EEST | Press release

ThredUp (Nasdaq: TDUP, LTSE: TDUP), one of the largest online resale platforms for apparel, shoes, and accessories, today announced the appointment of Florin Filote as the company’s General Manager of Europe. With nearly two decades of experience in retail and ecommerce with an emphasis on building and scaling marketplace businesses, Filote will oversee the company’s European business operations, which currently span nine countries in Central and Eastern Europe. He succeeds Dan DeMeyere, who has been with ThredUp since 2010 and most recently ran the company’s international business for two years. DeMeyere is transitioning back to the U.S. business to scale technology and artificial intelligence innovation as Chief Product and Technology Officer. Filote and DeMeyere will both report to ThredUp CEO and Cofounder James Reinhart. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502300242/en/ Florin Filote, General Manager of Eu

Stallergenes Greer Publishes in the Lancet Regional Health-Europe Landmark EfficAPSI Real-world Study Confirming Significant Benefit of Its Liquid Sublingual AIT on the Onset and Progression of Allergic Asthma2.5.2024 11:23:00 EEST | Press release

Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced that results of its EfficAPSI real-world study evaluating the impact of Stallergenes Greer liquid sublingual AIT (SLIT-liquid) on asthma onset and evolution in patients with allergic rhinitis have been published in the Lancet Regional Health-Europe. The publication is available online (https://doi.org/10.1016/j.lanepe.2024.100915) and will be available in print at a later date. This retrospective longitudinal pharmaco-epidemiological real-world study, which evaluated data over a 9-year period, included over 440,000 patients: more than 110,000 patients with allergic rhinitis, with or without asthma, treated with Stallergenes Greer SLIT-liquid and symptomatic drugs; compared to more than 330,000 patients with allergic rhinitis, with or without asthma, treated with symptomatic drugs only. The primary objective of the study was the evaluation of the real-world impact of Stallergene

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye